Time To Efficacy and Onset Of Action Of Linezolid

Phase 4

Completed

• Conditions: Gram-Positive Bacterial Infections; Skin and Connective Tissue Diseases

• Registration Number: NCT00147511
• Lead Sponsor: Pfizer

Brief Summary

To assess the onset of action of linezolid

Detailed Description

Not available

Study Timeline

• Study Start: 2003-06
• Study Completion: 2005-06
• Study First Submitted: 2005-09-02
• Study First Submitted QC: 2005-09-02
• Study First Posted: 2005-09-07
• Status Verified: 2011-05
• Last Update Submitted: 2011-05-09
• Last Update Posted: 2011-05-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 118

Inclusion Criteria

• suspected grampositive infection
• fever > 38 C

Exclusion Criteria

• Infections to be treated successfully by surgical procedures

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Time to defervescence

Secondary Outcome Measures

Name	Time	Method
Reduction of CRP levels Reduction of leucocyte count